Court Orders AbbVie to Release Marketing Documents in FTC Case

A federal judge has ordered AbbVie to release documents to the Federal Trade Commission related to its marketing of its testosterone treatment AndroGel.

U.S. District Court Judge Harvey Bartle III ruled that AbbVie must hand over to the FTC any documents that show the company’s board of directors discussing the marketing or sale of AndroGel no later than Aug. 22.

The FTC alleges that AbbVie and its partner, Besins Healthcare, entered into groundless patent infringement disputes with two generics companies with the goal of postponing generic competition. The agency filed suit for access to the documents in 2014.